China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Lev Facher covers the U.S. addiction and overdose crisis. The significant, recent decline in U.S. drug overdose deaths was driven in large part by a sudden shift in North America’s illicit drug supply ...

A clear breakdown of the process, showing each step in detail to help viewers understand techniques, methods, and the reasoning behind every action. Hegseth censures Sen. Kelly after warning about ...

David joined Raw Story in 2023 after nearly a decade of writing about the legal industry for Bloomberg Law. He is also a co-founder and a commissioning editor at Hypatia Press, a publisher that ...

A new project seeking to transform the drug delivery process and take projects out of “the valley of death” between aspiration and accomplishment is getting help from La Jolla-based medical research ...

Chicago-based Amphix Bio has raised $12.5 million in seed funding to advance its experimental paralysis-reversing drug toward human trials, the Northwestern University spinout announced today. The ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, CDMOs Bora Pharmaceuticals and Corealis Pharma understand that oral solid ...

Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a severe form of fatty liver disease in drug trials, the ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise ...

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, ...